KalVista Pharmaceuticals (KALV) Short-term Investments (2019 - 2025)

KalVista Pharmaceuticals (KALV) has 7 years of Short-term Investments data on file, last reported at $67.2 million in Q3 2025.

• For the quarter ending Q3 2025, Short-term Investments fell 52.84% year-over-year to $67.2 million; the trailing twelve-month figure through Jul 2025 stood at $67.2 million (down 52.84% YoY), and the FY2025 full-year result was $89.0 million, down 50.17% from the prior year.
• Short-term Investments eased to $67.2 million in Q3 2025, from $89.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $198.3 million in Q2 2021 to a low of $32.6 million in Q1 2021.
• A 5-year average of $108.3 million and a median of $93.1 million in 2023 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments soared 357.93% in 2022 and tumbled 52.84% in 2025, its largest moves.
• Tracing KALV's Short-term Investments over 5 years: stood at $163.3 million in 2021, then plunged by 48.76% to $83.7 million in 2022, then slumped by 45.62% to $45.5 million in 2023, then surged by 89.03% to $86.0 million in 2024, then dropped by 21.92% to $67.2 million in 2025.
• Business Quant data shows KALV's Short-term Investments at $67.2 million in Q3 2025, $89.0 million in Q2 2025, and $86.0 million in Q4 2024.